Cobimetinib is a third-generation MEK inhibitor that has been evaluated in combination with the BRAF inhibitor vemurafenib in R/R extramedullary MM harboring the BRAF V600E mutation [93]. Here, MAP2K7 is linked to Miyoshi myopathy.